BioSpace News Archive

NEOGEN Corporation announced that its Genetic Veterinary Sciences, Inc. facility has received ISO/IEC 17025:2017 accreditation from the American Association for Laboratory Accreditation — the highest recognized quality standard in the world for testing and calibration laboratories.

Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) today announced that Pravin Chaturvedi, PhD, a pharmaceutical veteran and leading clinical development expert, has been appointed Chief Scientific Officer (CSO) and Chair of the Scientific Advisory Board (SAB) of Jaguar.

Evotec SE will announce its financial results for 2021 on Tuesday, 12 April 2022.

Avidity Biosciences, Inc., a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, announced that Michael MacLean, currently the chief financial officer, has expanded his role to include responsibilities as chief business officer.

Know Labs, Inc. (OTCQB: KNWN), an emerging leader in non-invasive medical diagnostics, today announced it has been granted two new foundational patents that add significant value to its IP portfolio and proprietary Bio-RFID™ technology.

Alira Health, a global health care advisory and technology company, announced that it has acquired a full-service Contract Research Organization, Sourcia, that provides services for Phase I to Phase IV clinical trials with a focus on biotech, medical devices, and digital therapeutics.

Oxford Finance LLC is announcing the closing of a $75 million senior secured term loan with Fusion Pharmaceuticals Inc., a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines to treat a broad range of cancers.

Structured as a program-related investment in the form of a loan, the Helmsley funding supports the early clinical development of TP-317.

Cordis today announced a strategic investment venture that will expand the scope of the global cardiovascular technology company into the Venous Thromboembolism Market (VTM) with a strategic investment in Endovascular Engineering (“E2"), a developer of next-generation thrombectomy devices to treat patients with Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE).

Med-Metrix, LLC (“Med-Metrix”, or the “Company”), a leading provider of technology-enabled, Revenue Cycle Management (“RCM”) solutions, backed by A&M Capital Partners (“AMCP”), announced it has acquired ARMCO Partners, LLC (“ARMCO”).